Gilead Sciences, INC 10-Q quarterly reports

Gilead Sciences reports Q1 2026 revenue of $6.96 billion and announces significant strategic acquisitions in oncology and immunology.

Gilead Sciences reported a significant increase in net income and diluted EPS for Q3 and the first nine months of 2025, driven by a $400 million intellectual property sale and substantially lower impairment charges compared to the prior year.

Gilead Sciences reported a 2% increase in total revenues for Q2 2025, driven by strong HIV product sales, while navigating pipeline impairments and ongoing legal challenges.

Gilead Sciences' Q1 2025 results show stable revenue driven by HIV product sales, offsetting declines in Veklury and Oncology, with a net income rebound compared to a loss in the previous year.

Gilead Sciences' Q3 2024 results show a net loss driven by significant R&D impairments, despite a revenue increase.

Gilead Sciences' second-quarter results show a revenue increase but a net loss due to significant R&D expenses and impairments.

Gilead Sciences' first quarter 2024 results were significantly impacted by acquisition costs and an impairment charge, leading to a net loss despite a revenue increase.